4BIO Capital intends to take gene and cell therapies mainstream
Category: #health  By Pankaj Singh  Date: 2019-09-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

4BIO Capital intends to take gene and cell therapies mainstream

The venture capitalist firm has secured an investment of $50 million and is expecting to gather an investment of up to $150 million till 2020.

4BIO Capital, a London-based firm investing in Public Equities in Life Sciences and Venture Capital, has made headlines for raising $50 million (€45 million) to finance advanced therapy startups. The leading venture capital firm intends to invest the money, with an additional $100 million which it expects to add by the final close, into those firms that are focused on extending the use of improved therapies to critical diseases such as rheumatoid arthritis and diabetes.

As per reports, 4BIO has secured the $50 million commitment, involving a cornerstone investment from Children’s Minnesota, a U.S pediatric hospital, for its next advanced therapy VC fund accompanied by the previous successful investments in companies like Orchard Therapeutics. Currently, the firm aims to improve the advanced therapy sector and wants to demonstrate efficiency in critical diseases. 

Speaking on the move, Dmitry Kuzmin, Managing Partner, 4BIO, said that the company is focused on evolving advanced therapies from their historical stage of monogenic genetic disorders and super-rare diseases to a larger, more publicly significant indications where the firm openly has thousands of patients. 

Reportedly, a string of milestone gene and cell therapy approvals have turned the firm’s perceptions, allowing it to research on major diseases and appeal the investment needed to bankroll their elaborate strategy. 

According to Kuzmin, the company is delighted by the level of interest it has gained and is now witnessing a considerable growth of interest in Institutional investors.

Moreover, that interest has resulted in commitments of above $50 million. The company eventually expects to have an investment of $150 million until it holds the final close of the fund in the Q3&4 of 2020.

Additionally, the company will put the investment in developers of gene and cell therapies, targeted treatments, the microbiome and RNA-based candidates, with a quarter of the money going to the firms created by 4BIO itself.

Source Credit: https://www.fiercebiotech.com/biotech/4bio-raises-vc-fund-to-take-cell-and-gene-therapies-mainstream



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...